Beijing Hotgen Biotech Co

Beijing Hotgen Biotech Co R&D per Employee

The R&D Spending per Employee of Beijing Hotgen Biotech Co (688068.SS) as of Nov 16, 2026 is 137,645.33 CNY. In the previous year, R&D Spending per Employee was 96,107.86 CNY — a change of 43.22% (higher).

R&D per Employee

137,645.33CNY

YoY

43.22%

Last updated:

R&D Spending per Employee of Beijing Hotgen Biotech Co is 2025 137,645.33 CNY. R&D Spending per Employee of Beijing Hotgen Biotech Co was 2024 96,107.86 CNY. It decreases by 43.22% higher compared to the previous year.

The Beijing Hotgen Biotech Co R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
15,592.37 CNY
Jan 1, 2019
24,589.21 CNY
Jan 1, 2020
40,383.36 CNY
Jan 1, 2021
111,888.39 CNY
Jan 1, 2022
162,119.34 CNY
Jan 1, 2023
112,707.79 CNY
Jan 1, 2024
96,107.86 CNY
Jan 1, 2025
137,645.33 CNY
The Beijing Hotgen Biotech Co R&D per Employee history
YEARR&D per EmployeeYoY
137,645.33CNY+43.22%
96,107.86CNY-14.73%
112,707.79CNY-30.48%
162,119.34CNY+44.89%
111,888.39CNY+177.07%
40,383.36CNY+64.23%
24,589.21CNY+57.70%
15,592.37CNY+17.59%
13,259.80CNY+17.59%
11,276.47CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beijing Hotgen Biotech Co Stock analysis

What does Beijing Hotgen Biotech Co do? Beijing Hotgen Biotech Co., Ltd. generates revenue through the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. The firm's product portfolio primarily consists of in vitro diagnostic reagents, in vitro diagnostic instruments, and biological raw materials. These offerings are designed to address clinical needs in areas such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections. Additionally, the products serve public safety applications including biosafety, food safety, and disease control and emergency response. The company operates in both domestic and overseas markets, selling its solutions to entities involved in clinical healthcare and public safety sectors. By providing specialized diagnostic tools and biological materials, Beijing Hotgen Biotech Co., Ltd. supports medical diagnosis and emergency response efforts globally. The business model relies on the direct sale of these manufactured goods to customers who require advanced diagnostic capabilities for disease detection and safety monitoring. Beijing Hotgen Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beijing Hotgen Biotech Co stock

R&D Spending per Employee of Beijing Hotgen Biotech Co is 137,645.33 CNY in 2025.

R&D Spending per Employee of Beijing Hotgen Biotech Co changed from 96,107.86 CNY to 137,645.33 CNY, representing a 43.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Beijing Hotgen Biotech Co since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Beijing Hotgen Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Beijing Hotgen Biotech Co

All Key Metrics — Beijing Hotgen Biotech Co